Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer
Status:
Completed
Trial end date:
2019-01-16
Target enrollment:
Participant gender:
Summary
Background:
- Cabozantinib is a drug that slows the growth of blood vessels that feed tumors. It is
approved for medullary thyroid cancer. However, studies have shown that prostate tumors
respond to it. Docetaxel and prednisone are standard treatments for advanced prostate cancer.
Researchers want to see if adding cabozantinib to these two drugs can be a safe and effective
treatment for this type of cancer.
Objectives:
- To test the safety and effectiveness of cabozantinib with standard treatments for advanced
prostate cancer.
Eligibility:
- Individuals at least 18 years of age who have advanced prostate cancer that has not
responded to standard treatments.
Design:
- Participants will be screened with a physical exam and medical history. Blood and urine
samples will be collected. Imaging studies will also be performed.
- Participants will receive the cancer drugs over 21-day cycles of treatment. They will
take docetaxel and cabozantinib on day 1 of each cycle. Each docetaxel infusion will
take about 1 hour. They will also take prednisone by mouth twice each day.
- Treatment will be monitored with frequent blood tests and imaging studies.
- Participants will continue to take the study drugs for as long as their cancer does not
worsen and side effects are not too severe.